Why Medical Affairs Is Increasingly in the Room
Formulary committee meetings used to be primarily a managed care or market access conversation. The medical affairs team's contribution was often upstream: generating the clinical evidence that market access teams would then present to payers. The actual formulary review meeting was typically handled by managed care liaisons and HEOR specialists working with medical directors at health plans and PBMs.
That division of labor is shifting, and for a meaningful reason. Formulary committees are asking more sophisticated clinical and pharmacoeconomic questions than they were a decade ago. The rise of value-based contracting, outcomes-based arrangements, and the expanded use of comparative effectiveness evidence in formulary decisions means that the scientific depth required in the room has increased. Managed care liaisons with primarily commercial backgrounds are increasingly joined by, or replaced by, medical affairs representatives who can speak directly to clinical data nuance, head-to-head trial design, and safety signal interpretation.
For medical affairs teams, this expanded role creates an operational challenge. The type of question that comes up in a formulary meeting, "What were the primary endpoint results in the BEACON subgroup analysis for patients with BRAF V600E mutations?" requires instant access to specific clinical data, not a general knowledge of the drug's profile. Being unprepared in a formulary committee meeting does not just lose the meeting. It signals to the payer medical director that your organization does not have deep command of your own clinical evidence.
What Payer Medical Directors Actually Ask
Formulary submissions are reviewed by pharmacy and therapeutics (P&T) committees and medical advisory boards that typically include physicians, pharmacists, and pharmacoeconomists. The questions they ask vary by product type, indication, and the committee's specific analytical focus, but several categories come up reliably.
Comparative efficacy and safety: how does your drug perform against the existing standard of care and against competing agents on formulary? For products without head-to-head trials, this typically means indirect treatment comparisons or network meta-analyses, and the committee will want to understand the methodological assumptions behind those comparisons. The question "how did you select the comparator set for the ITC?" is common, and the answer needs to be grounded in the published methodology, not a verbal summary from memory.
Real-world evidence: as more payers move to include real-world outcomes data in formulary decisions, questions about RWE studies, registry data, and claims-based analyses appear more frequently. The committee may have their own real-world data from their member population that they want to reconcile with your clinical trial results. Being able to quickly locate the relevant safety profile data from a post-marketing surveillance study or patient registry requires that document to be indexed and queryable, not sitting in a PDF on someone's laptop.
Budget impact and utilization: HEOR teams typically prepare formal budget impact models for formulary submissions, but medical directors often probe the clinical assumptions underlying those models. If the model assumes a specific patient population prevalence or a specific titration trajectory, the medical affairs representative may be asked to defend those clinical assumptions with primary evidence. This requires the ability to retrieve the relevant clinical data quickly and precisely.
The Preparation Window Is Shorter Than It Looks
A formulary committee meeting typically has a defined submission deadline several weeks in advance, but the preparation intensity concentrates in the final days before the meeting. Market access teams are completing the formal submission package; medical affairs is finalizing the clinical scientific narrative; HEOR is updating the budget impact model with the latest list price and utilization assumptions. The medical affairs contribution to the room, the person who can field clinical questions that market access cannot answer, needs to have command of a significant body of clinical evidence.
Consider what that preparation actually involves for a medical affairs professional attending a formulary review for an oncology product with three approved indications and a competitive landscape that includes four alternatives. The relevant clinical documents include the full clinical study reports for pivotal trials across all three indications, the current labeling and any supplemental NDAs filed since launch, published head-to-head comparator data, indirect treatment comparison publications, post-marketing safety data, and any HEOR publications specific to the indication under review. In aggregate, this may be 4,000 to 8,000 pages of indexed documents that the medical affairs representative needs to be able to navigate in real time during a meeting.
The preparation approach that scales is not memorization and not printing. It is having a curated, indexed collection that can be queried quickly. "What was the 24-month overall survival in the KEYNOTE-590 intent-to-treat population?" should not require opening a PDF and scrolling. It should be a five-second retrieval that returns the answer with the exact table and page number so the medical affairs professional can confirm the number and cite the source in the same breath.
Scientific Exchange Standards in Payer Settings
One area that requires care: the regulatory standards governing scientific exchange with payers differ in important respects from scientific exchange with HCPs. FDA guidance distinguishes between scientific exchange with healthcare professionals and health insurance payers, particularly for discussions of off-label use and health technology assessment-relevant data. The OIG guidance on pharmaceutical manufacturer relationships with formulary committees adds another layer of compliance context.
Medical affairs professionals in payer-facing roles need to understand which data they can proactively present, which data can only be shared on request, and what documentation standards apply to those exchanges. This is not a reason to limit scientific engagement with payers; it is a reason to conduct it precisely, with clear documentation of what was discussed and on what basis. The same source-grounding standard that applies in HCP scientific exchange applies here: every clinical data point shared in a formulary meeting should be traceable to a specific document with a specific page and section.
Building a Formulary-Ready Evidence Package
The practical preparation step that most organizations do well at is preparing the formal formulary dossier. The preparation step that is done less consistently is building the supplementary evidence package: the collection of source documents that medical affairs will draw from when the committee asks questions not covered in the dossier.
Building that supplementary package well requires making deliberate choices about which documents to include and how they are organized. Not all clinical documents belong in every formulary meeting prep collection. A formulary meeting focused on a cardiovascular indication does not need the oncology clinical study reports from a different program. The relevant collection for a specific formulary review is the subset of your clinical evidence base that intersects with the specific indication, patient population, and competitive context of that meeting.
When we describe a "knowledge collection" in the context of Argon, this is specifically what we mean: a curated subset of indexed documents assembled for a specific purpose, in this case a formulary meeting, where queries return results from that specific collection rather than the full document library. The structure matters because it shapes what shows up when the medical affairs professional searches during the meeting. A well-built formulary prep collection returns relevant answers quickly; an unstructured general library requires the user to filter out noise under time pressure.
After the Meeting: Documentation and Follow-Up
Formulary committee decisions are rarely made in a single meeting. A submission that does not achieve preferred formulary status at first review often goes through a reconsideration process, and the committee may request additional information. The medical affairs team needs to document what questions were asked, what data was cited in response, and what follow-up was committed to.
That documentation serves two purposes. First, it is a compliance record of the scientific exchange that took place in the meeting. Second, it is the input for the follow-up submission: if the committee asked for additional real-world evidence for a specific patient sub-group, that question needs to be answered with primary source documentation at the next meeting.
The teams that handle formulary reviews most effectively treat them as a sustained evidence management process, not a one-time submission event. Each meeting informs what evidence gaps need to be addressed, which directly feeds back into the medical affairs evidence generation strategy and, for products with active post-marketing studies, can even influence which endpoints in a registry study are worth prioritizing for early analysis.